Antibiotic prophylaxis proves cost-effective for patients at risk of fatal heart infection
- Guidelines advising dentists to stop prescribing antibiotics before invasive treatment are not efficient or cost effective
- Prescribing antibiotic prophylaxis could save the NHS up to £8.2 million annually
- There have been 35 extra cases of infective endocarditis every month in the UK since the NICE guidelines were introduced
A new study has shown guidelines from the National Institute for Health and Care Excellence (NICE) advising dentists to stop prescribing antibiotics before invasive treatment may not have been efficient or cost-effective.
A team of international researchers, led by Professor Martin Thornhill from the University of Sheffield’s School of Clinical Dentistry, along with health economists Professor Allan Wailoo and Dr Matthew Franklin from the School of Health and Related Research (ScHARR) also at the University of Sheffield, discovered the decision made by NICE in 2008 recommending dentists should stop prescribing antibiotic prophylaxis (AP) for those at risk of the life-threatening infective endocarditis (IE) is likely to be less cost-effective than providing the treatment.
The new economic evaluation showed that prescribing AP could save £5.5 million to £8.2 million annually for the NHS.
Professor Thornhill and his team previously estimated there had been 35 extra cases of IE every month in the UK in the period since the NICE guidelines were introduced.
IE is a rare but serious infection of the heart lining caused by infectious agents, or pathogens, which are largely bacterial.
“In 2008 NICE issued guidance that the use of antibiotic prophylaxis completely stop in the UK – despite it still being recommended everywhere else in the world,” said Professor Thornhill.
“One of the main reasons NICE gave against prescribing AP was a health-economic analysis that showed it not to be cost-effective. The problem was they had very little data on which to base their analysis and assumed the AP was not effective and that it was associated with frequent and severe side effects. This study shows that neither is true.”
Professor Thornhill added: “We replicated the NICE health-economic analysis using up to date data and the results show that AP is probably highly cost-effective and would save the NHS millions of pounds each year as well as improving the quality of life of and reducing death rates for those at risk of IE.”
The findings, which are presented today at the American Heart Association Meeting in New Orleans, show that only a marginal reduction in annual rates of infective endocarditis – 1.44 cases in high-risk and 33 cases in all at-risk patients – would be required for AP to be considered cost-effective.
For more information about the team’s previous studies please visit:
The University of Sheffield
With almost 27,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2016 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014. In the last decade it has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For further information, please visit www.sheffield.ac.uk
For further information please contact:
Media Relations Officer
University of Sheffield
0114 222 9859